Loading
Life sciences · Journal article
Frontiers in Oncology · September 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Ovarian cancer (OC) is the deadliest gynecological malignancy which continues to impose a significant challenge in the field of oncology research due to its rapid metastasis, inter and intra-tumor heterogeneity, and treatment resistance. Personalized medicine for OC is still under development where patient-derived organoids (PDO) represent as a promising platform intended towards patient-specific disease modelling, biomarker discovery and therapeutic response assessment. These PDOs generate elaborate, complicated and high dimensional data traversing imaging, advanced omics and pharmacological analyses. Artificial intelligence (AI) and machine learning (ML) approaches allow refined prognostic stratification of patients through improved target delineation and response prediction when integrated with bioinformatics and conventional statistics. This narrative review discusses the foundations laid on the organoid generation and AI-enabled evaluation of ovarian cancer PDOs. The successful translation of AI-guided strategies into clinical oncology will depend on rigorous multi-center validation, harmonized methodologies, and prospective clinical studies demonstrating improvements in patient outcomes and real-world applicability.